Prevalence of subclinical Non-Exudative choroidal neovascularisation and its contribution to prediction of exudatiON in fellow eyes with unilateral exudative AMD (EYE-NEON)

Moorfields Eye Hospital NHS Foundation Trust0 个研究点目标入组 800 人开始时间: 2021年7月20日最近更新: 2024年5月13日

适应症

试验速览

暂无简介。

•Consecutive patients at each site who meet the following inclusion and exclusion criteria:
•1. Adults who are >=50 years and <=100 years
•2. Fellow eyes of patients with unilateral treatment naïve neovascular AMD at baseline
•3. Media clarity, pupillary dilation and patient cooperation for adequate imaging
•4. Ability to give informed consent
•Inclusion criteria for retrospective part only in addition to above:
•1. Fellow eyes of patients with unilateral neovascular AMD initiated on treatment in the past 12-15 months
•2. Had OCT and OCTA for study eye at baseline

•1. Treatment initiation for unilateral neovascular AMD more than 15 months prior to recruitment.
•2. Late wet AMD in the study eye
•3. Co-existent ocular disease: Any other ocular condition that, in the opinion of the investigator, might affect or alter visual acuity during the course of the study
•4. Any patient who has opted out of their information being used for research nationally or locally at any site
•5. Patients participating in a clinical trial with an ophthalmic experimental therapy will be excluded
•6. Study eye (neCNV) is not treated with anti-VEGF within 6 months for non-wAMD reason

发起方